Imagion Biosystems Limited (IBX.AX)
- Previous Close
0.0120 - Open
0.0130 - Bid 0.0120 x --
- Ask 0.0130 x --
- Day's Range
0.0120 - 0.0130 - 52 Week Range
0.0110 - 0.0970 - Volume
516,117 - Avg. Volume
414,172 - Market Cap (intraday)
2.416M - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.
imagionbiosystems.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IBX.AX
View MorePerformance Overview: IBX.AX
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBX.AX
View MoreValuation Measures
Market Cap
2.42M
Enterprise Value
2.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
--
Enterprise Value/Revenue
2.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-77.56%
Return on Assets (ttm)
-12.65%
Return on Equity (ttm)
--
Revenue (ttm)
2.67M
Net Income Avi to Common (ttm)
-2.07M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-610.69k